# NKT2152

Source: https://onco.cc/drugs/nkt2152/  
OnCo record `nkt2152` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NKT2152 is an experimental pill from NiKang Therapeutics, in phase 2 trials for clear cell renal cell carcinoma.

## Summary

NKT2152 is a small molecule, oral from NiKang Therapeutics. An allosteric inhibitor of HIF-2α (HIF2-alpha) that breaks up the HIF2-alpha and HIF1-beta complex. Both NiKang-sponsored studies in clear cell renal cell carcinoma (NCT05119335 and NCT05935748, the second with palbociclib and sasanlimab) are terminated; the sources read do not say whether kidney cancer development continues. It is also one of the drugs in Roche's MORPHEUS-Liver platform study in liver cancer.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: NKT2152
- Modality: Small molecule, oral
- Mechanism: An allosteric inhibitor of HIF-2α (HIF2-alpha) that breaks up the HIF2-alpha and HIF1-beta complex.

## Sources

- NiKang science and pipeline: https://www.nikangtx.com/science-and-pipeline/
- ClinicalTrials.gov NCT04524871: https://clinicaltrials.gov/study/NCT04524871
- ClinicalTrials.gov NCT05119335: https://clinicaltrials.gov/study/NCT05119335
- ClinicalTrials.gov NCT05935748: https://clinicaltrials.gov/study/NCT05935748

## Connected records

- cancers: [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/)
- targets: [HIF-2α](https://onco.cc/targets/hif2a/)
- companies: [NiKang Therapeutics](https://onco.cc/companies/nikang-therapeutics/)
- trials: [A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma](https://onco.cc/trials/nct05119335/), [Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)](https://onco.cc/trials/nct05935748/)

---
JSON: https://onco.cc/api/v1/entities/nkt2152.json